Upstream Bio (UPB) Revenue (2023 - 2026)

Upstream Bio's (UPB) quarterly Revenue came in at $1.0 million in Q1 2026, up 82.69% year-on-year from $566000.0 in Q1 2025, and up 54.79% quarter-over-quarter from $668000.0 in Q4 2025.

Upstream Bio (UPB) Revenue (2023 - 2026) Analysis & Trends

Upstream Bio's Revenue history runs 4 years deep, the most recent figure standing at $1.0 million for Q1 2026.

  • On a quarterly basis, Revenue rose 82.69% year-over-year to $1.0 million in Q1 2026; TTM through Mar 2026 was $3.3 million, a 44.69% increase from a year earlier, with the FY2025 full-year figure at $2.9 million, up 20.42% from the prior year.
  • Revenue rose to $1.0 million in Q1 2026 per UPB's latest filing, from $668000.0 in the prior quarter.
  • Across five years, Revenue topped out at $1.0 million in Q1 2026 and bottomed at $450000.0 in Q4 2023.
  • The 4-year median for Revenue is $621000.0 (2023), against an average of $666272.7.
  • Biggest YoY gain for Revenue was 83.73% in 2025; the steepest drop was 11.56% in 2025.
  • Year by year, Revenue stood at $450000.0 in 2023, then soared by 36.22% to $613000.0 in 2024, then grew by 8.97% to $668000.0 in 2025, then jumped by 54.79% to $1.0 million in 2026.
  • Per Business Quant, the three latest UPB Revenue figures stand at $1.0 million (Q1 2026), $668000.0 (Q4 2025), and $683000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1.51 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 2.99 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 3.61 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 1.30 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Upstream Bio 343.65 Mn 343.65 Mn -3.94 Mn 1.03 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.03 Mn
Dec 31, 2025 668,000.00
Sep 30, 2025 683,000.00
Jun 30, 2025 937,000.00
Mar 31, 2025 566,000.00
Dec 31, 2024 613,000.00
Sep 30, 2024 607,000.00
Jun 30, 2024 510,000.00
Mar 31, 2024 640,000.00
Dec 31, 2023 450,000.00
Sep 30, 2023 621,000.00